“Discontinuation rate of dual antiretroviral therapy with dolutegravir plus lamivudine in people living with HIV: a systematic review”, RSD, vol. 11, no. 12, p. e430111234758, Sep. 2022, doi: 10.33448/rsd-v11i12.34758.